News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,708 Results
Type
Article (41273)
Company Profile (265)
Press Release (687154)
Multimedia
Podcasts (90)
Webinars (20)
Section
Business (204807)
Career Advice (2030)
Deals (35570)
Drug Delivery (128)
Drug Development (81493)
Employer Resources (173)
FDA (16487)
Job Trends (14976)
News (346737)
Policy (32749)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (45)
Adcomms (26)
Allergies (168)
Alliances (49579)
ALS (200)
Alzheimer's disease (1768)
Antibody-drug conjugate (ADC) (427)
Approvals (16848)
Artificial intelligence (633)
Autoimmune disease (254)
Automation (52)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (217)
Biotechnology (175)
Bladder cancer (184)
Brain cancer (68)
Breast cancer (721)
Cancer (5649)
Cardiovascular disease (455)
Career advice (1721)
Career pathing (41)
CAR-T (316)
CDC (54)
Celiac Disease (3)
Cell therapy (845)
Cervical cancer (46)
Clinical research (70561)
Collaboration (2007)
Company closure (5)
Compensation (1330)
Complete response letters (77)
COVID-19 (2734)
CRISPR (103)
C-suite (1066)
Cystic fibrosis (150)
Data (7520)
Decentralized trials (3)
Denatured (27)
Depression (157)
Dermatology (76)
Diabetes (572)
Diagnostics (6889)
Digital health (53)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (308)
Drug pricing (199)
Drug shortages (31)
Duchenne muscular dystrophy (274)
Earnings (91402)
Editorial (64)
Employer branding (21)
Employer resources (152)
Events (119013)
Executive appointments (1060)
FDA (20094)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (34)
Funding (1676)
Gene editing (224)
Generative AI (54)
Gene therapy (683)
GLP-1 (1035)
Government (4716)
Grass and pollen (6)
Guidances (403)
Healthcare (18969)
HIV (77)
Huntington's disease (54)
IgA nephropathy (93)
Immunology and inflammation (281)
Immuno-oncology (86)
Indications (175)
Infectious disease (3068)
Inflammatory bowel disease (204)
Inflation Reduction Act (14)
Influenza (135)
Intellectual property (284)
Interviews (318)
IPO (16657)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (18)
Labor market (96)
Layoffs (558)
Leadership (37)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (752)
Lymphoma (421)
Machine learning (58)
Management (59)
Manufacturing (989)
MASH (179)
Medical device (13899)
Medtech (13993)
Mergers & acquisitions (20128)
Metabolic disorders (1455)
mRNA (193)
Multiple sclerosis (182)
NASH (17)
Neurodegenerative disease (398)
Neuropsychiatric disorders (103)
Neuroscience (3229)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4527)
Now hiring (76)
Obesity (680)
Opinion (284)
Ovarian cancer (207)
Pain (244)
Pancreatic cancer (287)
Parkinson's disease (351)
Partnered (33)
Patents (577)
Patient recruitment (639)
Peanut (61)
People (59445)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21995)
Phase 2 (31080)
Phase 3 (23132)
Pipeline (7871)
Policy (308)
Postmarket research (2567)
Preclinical (9362)
Press Release (64)
Prostate cancer (289)
Psychedelics (52)
Radiopharmaceuticals (317)
Rare diseases (1028)
Real estate (5965)
Recruiting (70)
Regulatory (25244)
Reports (55)
Research institute (2411)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (20)
RSV (88)
Schizophrenia (175)
Series A (280)
Series B (207)
Service/supplier (11)
Sickle cell disease (109)
Special edition (22)
Spinal muscular atrophy (165)
Sponsored (47)
Startups (3633)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (61)
Vaccines (1078)
Venture capital (103)
Weight loss (438)
Women's health (120)
Worklife (20)
Date
Today (224)
Last 7 days (727)
Last 30 days (2798)
Last 365 days (30209)
2026 (10460)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (740)
Alabama (91)
Alaska (7)
Arizona (342)
Arkansas (14)
Asia (39592)
Australia (6488)
California (12781)
Canada (3657)
China (1296)
Colorado (547)
Connecticut (552)
Delaware (389)
Europe (85579)
Florida (1919)
Georgia (411)
Hawaii (3)
Idaho (62)
Illinois (1021)
India (88)
Indiana (583)
Iowa (23)
Japan (513)
Kansas (129)
Kentucky (50)
Louisiana (39)
Maine (75)
Maryland (1535)
Massachusetts (9097)
Michigan (354)
Minnesota (694)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (138)
New Hampshire (84)
New Jersey (3385)
New Mexico (28)
New York (3360)
North Carolina (1620)
North Dakota (8)
Northern California (6374)
Ohio (379)
Oklahoma (23)
Oregon (41)
Pennsylvania (2577)
Puerto Rico (28)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5030)
Tennessee (206)
Texas (2021)
United States (45167)
Utah (380)
Vermont (1)
Virginia (306)
Washington D.C. (80)
Washington State (1026)
West Virginia (4)
Wisconsin (122)
Wyoming (2)
728,708 Results for "genvivo inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2025
·
6 min read
Press Releases
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
September 11, 2025
·
5 min read
Drug Development
GenVivo Announces Initiation of Patient Dosing in a US Phase I/Ib Clinical Trial Evaluating GEN2, a Personalizing, Gene Vector Immunotherapy, in Patients with Advanced Solid Tumors
GenVivo, Inc. announced that it has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2.
June 27, 2024
·
5 min read
Press Releases
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
·
5 min read
Press Releases
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
·
5 min read
Press Releases
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Gene Vector Therapy, at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 11, 2024
·
5 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
Press Releases
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
April 30, 2026
·
1 min read
Press Releases
Axogen, Inc. Reports First Quarter 2026 Financial Results
April 28, 2026
·
18 min read
Press Releases
Carlsmed, Inc. To Participate in Upcoming Investor Conferences - April 28, 2026
April 29, 2026
·
1 min read
1 of 72,871
Next
